Report from the inaugural 2025 Asia-UK Maternal-Neonatal Infection and Immunity Network (AMMuNet) symposium [0.03%]
2025年亚洲-英国妇幼感染与免疫网络（AMMuNet）首次研讨会报告
Suraj Bhattarai,Pritha Adhikari,Kalpana Subedi et al.
Suraj Bhattarai et al.
The Asia-UK maternal-neonatal infection and iMMunity Network (AMMuNet) convened its first international symposium in Kathmandu, November 2025, to address global and regional burden of maternal-neonatal infections. Primary objective of the s...
Alan D T Barrett,Richard E Rupp,Richard W Titball et al.
Alan D T Barrett et al.
Scientific synergy between prophylactic and therapeutic HIV vaccines-prevention and cure [0.03%]
预防与治愈：HPV预防性疫苗和治疗性疫苗之间的科研协同效应
Milton Maciel Jr,Lindsey R Baden,Katharine J Bar et al.
Milton Maciel Jr et al.
On January 13, 2026, the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), convened a virtual workshop to examine how advances in preventive and therapeutic HIV research can...
Fraction of viable virus particles in live varicella vaccine influences the profile of immune response [0.03%]
活痘疫苗中的活性病毒颗粒比例会影响免疫反应特征
Xuhua Duan,Zhuowei Shi,Yuchan Zhang et al.
Xuhua Duan et al.
Compared with inactivated vaccines, live attenuated vaccines can theoretically induce potent cellular and humoral responses through both exogenous and endogenous antigen-presentation pathways. However, the percentage of live virus particles...
Preserved SARS-CoV-2 T-cell responses despite impaired humoral immunity in children with profound B-cell lymphopenia [0.03%]
重症B细胞淋巴细胞减少的儿童SARS-CoV-2细胞免疫反应保存但体液免疫受损
Sabryna Nantel,Samuel Sassine,Benoîte Bourdin et al.
Sabryna Nantel et al.
Defining vaccine-induced protection in children with humoral immunodeficiency is essential to guide SARS-CoV-2 vaccination strategies in this high-risk population. We conducted a longitudinal analysis of SARS-CoV-2 immunity at 1, 6 and 12 m...
Multiorgan Outcomes Following BNT162b2 mRNA Vaccination vs SARS-CoV-2 Infection: A 30-Million-Person Real-World Cohort Analysis [0.03%]
BNT162b2 消息疫苗接种与 SARS-CoV-2 感染后的多器官结局：一项基于 3000万人的现实队列研究分析
Eman A Toraih,Dara Bruce,Mohammad H Hussein et al.
Eman A Toraih et al.
SARS-CoV-2 infection and BNT162b2 mRNA vaccination carry distinct cardiovascular risk profiles, yet direct comparative evidence across all immunological exposure groups and both sexes remains limited. Using the TriNetX Research Network (Dec...
Ekaterina V Ovcharenko,Marina R Patysheva,Kirill M Kirilenko et al.
Ekaterina V Ovcharenko et al.
The fast evolution of mRNA-based cancer therapeutics requires advanced frameworks to overcome the challenges of tumor heterogeneity and the immunosuppressive tumor immune microenvironment. In this context, single-cell technologies enable ch...
Enhui Dai,Dongjie Sun,Yifan Wu et al.
Enhui Dai et al.
Brucellosis remains a major global challenge to both animal production and public health. Brucella abortus A19, are limited in their application due to residual virulence and interference with serodiagnosis. The intracellular survival and i...
Essie Komla,Connor Whalen,Oscar B Torres et al.
Essie Komla et al.
Opioid use disorder (OUD) remains a global public health concern, exerting a significant economic burden on societies worldwide. To combat the rise of substance use disorder, a complementary vaccine-based intervention was developed to suppo...
Safety and immunogenicity testing of a melioidosis subunit vaccine candidate in cynomolgus macaques [0.03%]
一种贝氏疟原虫子体疫苗候选疫苗的安全性和免疫原性在食蟹猴中的试验结果
Sineenart Sengyee,Caitlyn E Orne,Sarah B Weiby et al.
Sineenart Sengyee et al.
Burkholderia pseudomallei, the etiologic agent of melioidosis, is a Gram-negative bacterial pathogen that causes severe disease in humans and animals. In this study, we evaluated the safety and immunogenicity of our lead melioidosis subunit...